Pleomorphic xanthoastrocytoma (PXA) is a slow-growing neoplasm that predominantly affects the pediatric and young adult population. This neoplasm has a good prognosis, with a median 10-year survival rate of 70%. The majority of tumors are supratentorial and arise in the temporal lobe, while spinal tumors are extremely rare, with only 8 reported cases. Molecular perturbations involving the MAPK/ERK signaling pathway have been described in PXAs. The most common mutation is BRAF V600E in 60%-80% of cases. Other mechanisms activating this pathway in the absence of this mutation are rare and include CRAF (RAF1) fusion genes. We report a PXA case in the cervical spinal cord of a 49-year-old man with slowly progressive coordination difficulties and extremity numbness. The tumor was negative for the V600E mutation, but 2 RNA sequencing platforms detected a QKI-RAF1 fusion (t(6; 3)(q26; p25)), which has not been previously reported in PXAs. This fusion is known to activate MAPK/ERK and PI3K/mTOR signaling. Although firstand second-generation RAF inhibitors are predicted to be ineffective, this fusion may be targetable by the novel RAF inhibitor LY3009120 and to some extent by the MEK inhibitor trametinib. Genetic analysis to screen for MAPK/ERK pathway mutations is warranted on PXAs negative for the V600E mutation.
INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA) is an uncommon, slow-growing WHO grade II glial neoplasm that predominantly occurs in the pediatric and young adult population (1) . Superficial and cystic presentations of this neoplasm without atypical histologic features generally have relatively good prognoses, while PXAs that are solid, deep, or have anaplastic histologic features tend to have less favorable prognosis. The overall survival rate is 80% at 5 years and 70% at 10 years (1) . While the diagnosis can be challenging, histologic features supporting PXA include pleomorphic cells with xanthomatous change, abundant reticulin, and eosinophilic granular bodies. Other helpful diagnostic features can include a spindle-cell component, absence of infiltration or limited infiltration, and leptomeningeal involvement (1) . The majority of tumors arise in the temporal lobe, while spinal tumors are extremely rare, with only 8 cases reported in the literature (2) (3) (4) (5) . Recently, genetic alterations in the MAPK/ERK signaling pathway have been found to be common in PXAs, particularly mutations in the RAF family of kinases (6) . RAF proteins are serine/threonine kinases downstream of RAS in the MAPK/ERK signaling pathway. RAF mutations and rearrangements cause constitutive pathway activation resulting in tumorigenesis (7) . The prevalence of the most common RAF alteration in PXAs, the BRAF V600E mutation, is 60%-80% (7). Since the discovery of the V600E mutation in PXAs and other gliomas, targeted pathway inhibitors have been successfully used to treat the afflicted patients (8, 9) . However, the remaining 20%-40% of PXA cases, although histologically identical, have less easily identifiable molecular aberrations. The second type of alteration, RAF fusions, while common in pilocytic astrocytomas, is thought to be rare in PXAs. Recently, activating RAF fusions including NFR1-BRAF, ATG7-RAF1, and TMEM106B-BRAF have been described in lowgrade and anaplastic PXAs without the classic V600E point mutation (10, 11) . We report a case of a PXA in an uncommon spinal location positive for QKI-RAF1 fusion, which has not been previously reported in a PXA.
MATERIALS AND METHODS

Case Presentation
Consent for research was obtained according to a protocol approved by the UT Southwestern IRB. The patient was a 49-year-old right-handed man with a history of a traumatic injury to his right arm, which resulted in a modest functional impairment. Four years later, he developed repeating shaking episodes of the right hand with some loss of coordination, which he attributed to his prior traumatic injuries. Nine years after the accident, he developed episodes of right-sided numbness extending from his neck inferiorly as well as decreased coordination of his right hand. Cervical spinal cord MRI with contrast showed an intradural extramedullary contrast enhancing mass along the anterolateral surface of the spinal cord from C3-4 to C6-7 with enhancement extending along the anterior nerve roots (Fig. 1A, B) . Cerebrospinal fluid cytology was negative for malignancy. A repeat cervical spinal MRI 8 months later showed increasing enhancement along the anterior aspect of his spinal cord from C3 to C7, encasing multiple spinal rootlets. The patient underwent a subtotal resection through a C4-5 laminectomy. Intraoperatively, a firm, yellowish, moderately vascular lesion extending to the pial surface was identified. The patient had an uncomplicated postoperative course and is undergoing radiation therapy without evidence of recurrence at least 7 months after the initial diagnosis.
Next-Generation Cancer Gene Panel
The Tempus xO assay was performed on unstained sections cut from a formalin-fixed, paraffin-embedded (FFPE) block of tumor tissue and a matched germline saliva. This assay combines a 1711 gene targeted somatic and germline DNA sequencing panel with RNA sequencing to detect both germline and somatic single nucleotide polymorphisms, indels, copy number variants, and gene rearrangements causing chimeric mRNA transcript expression. Detailed steps are outlined in the Supplementary Methods.
RNA Fusion Confirmation
Confirmation of the RNA fusion results was obtained in a different laboratory using different methodology. Following the previously lab-developed RNAseq assay, RNA was extracted from paraffinized sections using an AllPrep DNA/ RNA FFPE kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. The RNA was reverse transcribed into cDNA and used for NGS library preparation using the Trusight RNA Pan-Cancer Panel Kit (Illumina, San Diego, CA), according to the manufacturer's protocol. Massive parallel sequencing was performed on an Illumina MiSeqDx flow cell with Illumina BaseSpace Workflow (v1.1.0) and analyzed using Isis software (v2.6.25.18) and manual inspection.
RESULTS
The neoplasm was histologically composed of pleomorphic, often multinucleated cells with moderately abundant, eosinophilic cytoplasm as well as spindle-shaped cells arranged in fascicles. Scattered eosinophilic granular bodies were present. Occasional cells demonstrated a xanthomatous change (vacuolation) (Fig. 1C, D) . No infiltrative foci, microvascular proliferation, or areas of necrosis were identified. There were no SMI-31-immunopositive axons traversing the tumor, which is consistent with a noninfiltrative neoplasm. The tumor lacked CAM5.2 immunohistochemical (IHC) staining, but was immunoreactive for GFAP, MAP-2, and synaptophysin (patchy), consistent with PXA (Fig. 1E, F) . The MIB-1 proliferation index was very low (approximately 0.5%). An immunostain for the mitotic marker PHH-3 was negative. A special stain for reticulin highlighted a reticulin-rich stromal network (Fig. 1G) . The criteria for anaplastic PXA (WHO grade III) were not met in this case. Tumor was negative for the BRAF V600E mutation by IHC. As a part of a nextgeneration sequencing cancer gene panel, RNA sequencing was performed and demonstrated a QKI-RAF1 fusion in tumor cells but not in unaffected tissue. This fusion resulted from a break after amino acid position 134 in exon 3 encoding a KH domain (K homology RNA binding domain) and RNAbinding domain in the QKI gene and a break after amino acid position 278 in exon 8 encoding a protein kinase domain in the RAF1 gene ( Fig. 2A, B) . To elucidate a possible mechanism of action of this fusion, IHC for phospho-ERK/MAPK was performed and showed positive immunoreactivity in tumor cells (Fig. 1H) .
DISCUSSION
PXA is a relatively uncommon neoplasm that often presents a diagnostic challenge for the pathologist. Recently, MAPK/ERK signaling pathway alterations have been identified in these tumors, serving as ancillary diagnostic tools to histopathologic examination. The most common aberration, the BRAF V600E mutation, now easily identifiable by immunohistochemistry, is present in up to 80% of PXAs (7), and has been targeted by specific inhibitors (8, 9) . However, the remaining PXA cases have less easily identifiable molecular aberrations. While a single QKI-RAF1 translocation was reported in a 5-year-old female patient with a pilocytic astrocytoma in the diencephalon (6), it has not previously been reported in a PXA. This is the first reported case of an extremely uncommon spinal PXA with a QKI-RAF1 chromosomal fusion.
QKI alterations in the brain have been previously described-QKI fusion with MYB was reported in angiocentric gliomas (12) . QKI (quaking) is an RNA-binding protein that regulates glial development and central nervous system myelination. It functions as a tumor suppressor while its activating rearrangements serve to drive tumorigenesis. The QKI-RAF1 fusion contains N-terminal QKI exons 1-3 encoding QKI homodimerization domain and part of its RNA-binding domain, and the truncated C-terminal portion of RAF1 containing exons 8-17 encoding the kinase domain. Similar to most BRAF fusions, QKI-RAF1 lacks the N-terminal noncatalytic, inhibitory domain of RAF but retains the functional kinase domain. Similar fusions with the loss of the N-terminal regulatory RAF1 domain have been shown to result in constitutive RAF1 kinase activity, leading to activation of downstream MEK1/2 cascade and increased proliferation of cancer cells (13) . The loss of N-terminal regulatory domains of RAF1 is thought to be driving oncogenic properties in vitro and is the basis of the mechanism of action for this fusion. In this case, the QKI-RAF1 fusion correlates with the aberrant expression of pERK/ MAPK in PXA tumor cells and further corroborates this notion.
RAF fusions, while common in pilocytic astrocytomas, are uncommon in PXAs. Recently, a case of PXA with a CRAF fusion was reported (11) . RAF inhibition has been used clinically for tumors with BRAF mutations and fusions, however, the data on CRAF/RAF1 are limited. CRAF fusions activate both the MAPK/ERK and PI3K/mTOR pathways, and, unlike BRAF fusions, are unresponsive to both first-and second-generation RAF inhibitors, which is thought to be due to CRAF dimerization. It has been shown that immunodeficient mice with intracranially injected Tp53-null primary mouse astrocytes stably expressing QKI-RAF1 demonstrated response to compound LY3009120, which was shown to inhibit the fusion by preventing dimerization-dependent oncogenic signaling activation (14) . While no FDA-approved targeted therapy is yet available for tumors with this fusion in any organ system, a patient with metastatic melanoma harboring a different CRAF fusion (ANO10-RAF1) showed a significant clinical response to MEK inhibitor (15) .
Given the variable response of glial tumors to targeted RAF inhibitors depending on the specific nature of genetic alteration, and the emerging data on the potential utility of pan-RAF inhibitors and combination therapy targeting both the MAPK/ERK and PI3K/mTOR pathways, histopathologic examination and routine IHC for BRAF V600E should be supplemented with genetic analysis to detect other MAPK/ERK pathway alterations in the absence of V600E mutation. A lowcost and timely IHC on pERK can alternatively be performed as done in this case to specifically screen for this pathway activation when genetic sequencing is unavailable. This approach Spinal PXA With a QKI-RAF1 Fusion
